Oscar Health, Inc. (NYSE:OSCR) shares closed 11.9% lower at $26.54 on August 6, even after the insurer reported its most profitable first half and raised its full-year outlook. Second-quarter revenue rose 70% year over year to $4.88 billion, while the company swung to net income of $361.8 million from a $228.4 million loss. The stock recovered 5.1% the following day but still ended 7.3% below its pre-earnings close.
The reversal was especially striking because OSCR had climbed roughly 110% in 2026 before the report. Investors had already rewarded the company for appearing to emerge from the Affordable Care Act market reset with stronger pricing and more members. The quarter confirmed much of that progress, but it also showed why the first half cannot simply be annualized.
Coverage of the selloff centered on management’s discussion of second-half utilization, risk adjustment and membership churn. The issue was not whether Oscar had improved. It was whether that improvement would survive a more demanding second half and a less predictable ACA enrollment pool.
THE CONSTRUCTIVE CASE
The constructive case starts with the breadth of the improvement. Oscar’s medical loss ratio fell to 79.2% from 91.1% a year earlier. Oscar calculates the ratio by comparing medical expenses with net premiums before ceded quota-share reinsurance, with risk adjustment reflected in the premium base. On that measure, medical costs consumed a much smaller share of premiums than they did a year ago.
Management estimated that the second-quarter ratio would have been approximately 82% without favorable prior-period development. The selling, general and administrative expense ratio also declined to 14.2% from 18.7%, reaching what management described as a company record.
Those two ratios matter for different reasons. Better pricing and claims performance strengthened the insurance operation, while fixed-cost leverage and technology-driven efficiencies allowed Oscar to support a much larger membership base without administrative expenses rising at the same rate. The combination produced $388.6 million of operating income in the quarter, compared with a $230.5 million operating loss a year earlier.
The growth also came against a contracting ACA market. February 2026 effectuated Marketplace enrollment totaled 19.17 million, down 12% from February 2025. Oscar, by contrast, ended June with 2.96 million effectuated members, up 46% year over year. Set against the broader contraction, that growth is consistent with substantial market-share gains as several competitors reduced their footprints or exited markets. Scale is especially valuable here because spreading administrative costs across more members helps reinforce the expense-ratio improvement.
Management raised full-year operating-income guidance to $500 million–$700 million from $250 million–$450 million. It also improved its medical-loss-ratio outlook to 81.5%–82.5% from 82.4%–83.4%.
On the earnings call, management said the first 2026 Wakely industry claims report, covering claims through April, was favorable to Oscar’s assumptions. The company incorporated only a small part of that potential benefit into guidance. If the trend persists, the revised outlook may still contain some cushion.
THE SKEPTICAL CASE
The bear case is that the headline figures made Oscar’s earnings look more durable than they have yet proved to be.
First, the quarter included $164 million of favorable prior-period reserve development, driven largely by a $160 million favorable adjustment from the final 2025 CMS risk-adjustment report. Oscar recorded $232 million of favorable prior-period development across the first half, compared with a $250 million increase in the midpoint of its operating-income guidance. Much of the guidance increase therefore came from favorable development on prior periods, not only from stronger performance in the current book.
Second, the company’s own outlook points to a sharp seasonal reversal. Oscar generated $1.09 billion of operating income in the first half, yet expects only $500 million–$700 million for the full year. By subtraction, the forecast implies a second-half operating loss of roughly $393 million–$593 million. The implication is straightforward: first-half profit was never a new quarterly run rate.
Medical costs are already moving in that direction. The medical loss ratio rose from 70.5% in the first quarter to 79.2% in the second, and management expects it to increase further as the year progresses.
More members shifted from Silver plans into higher-deductible Bronze coverage for 2026. Those plans can delay insurer-paid costs while members work through their deductibles, with additional care potentially moving into the second half before deductibles reset in 2027. Oscar’s medical expenses increased 17% from the first quarter, a pattern management described as consistent with that seasonality.
Risk adjustment adds another layer of uncertainty. Because Oscar’s members skew younger, healthier, and more urban than the overall ACA population, the company is generally a net payer into the program. It expects risk-adjustment transfers to equal approximately 20% of direct policy premium revenue in 2026. The final amount depends partly on the relative health of members enrolled with competing insurers, leaving Oscar exposed to changes in marketwide morbidity that it cannot fully observe in real time.
Membership adds to that lack of visibility. The 2.96 million members reported at the end of June were up sharply from a year ago but down 6.7% from 3.17 million at the end of March. Oscar also expects monthly churn in the second half to run closer to twice the 1%–2% rate it previously anticipated as CMS eligibility checks lead to disenrollments.
Management has already reflected that churn in guidance and expects it to affect enrollment timing rather than revenue. Even so, the shift makes Oscar’s normalized membership and risk mix entering 2027 harder to read.
That distinction helps explain the selloff. After a roughly 110% rally, investors were being asked to value a first-half profit peak before the most difficult claims and enrollment data had arrived.
INSIDER MONKEY’S HEDGE FUND DATA ANALYSIS
Insider Monkey’s hedge fund database shows that 41 hedge funds held positions in Oscar Health, Inc. (NYSE:OSCR) at the end of the first quarter of 2026, compared with 47 funds at the end of the preceding quarter.
Those figures reflect holdings as of March 31, before OSCR’s first-half results.
CONCLUSION
Wall Street’s response centered on the much weaker second-half earnings pattern embedded in Oscar’s full-year outlook. Favorable reserve development, rising utilization and uncertainty around risk adjustment made the record first-half result a poor proxy for the rest of 2026.
The operating turnaround is nevertheless genuine. Oscar expanded rapidly against a shrinking ACA market, lowered its medical loss ratio even after excluding favorable prior-period development, and pushed administrative costs to a record-low share of revenue. Those gains extend beyond the benefit from reserve development.
The next test is whether Oscar can keep its reported full-year medical loss ratio within the 81.5%–82.5% range as Bronze-plan deductibles are exhausted, while holding risk-adjustment transfers near 20% of direct policy premium revenue. Meeting those targets through the second half would show that the earnings-day decline reflected concern about seasonality rather than a broken turnaround. A material miss would justify the market’s reluctance to capitalize a first-half profit peak.
While we acknowledge the risk and potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OSCR and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
